连续生物製程市场－全球产业规模、份额、趋势、机会及预测（依产品、製程、应用、最终用户、地区及竞争格局划分），2021-2031年

全球连续生物加工市场预计将从 2025 年的 2.6487 亿美元成长到 2031 年的 4.6439 亿美元，复合年增长率为 9.81%。

该领域的核心在于生物材料在加工单元中连续流动，同时添加培养基并收穫最终产品。这种方法的主要驱动力在于，需要在提高高混合生产效率和柔软性的同时，最大限度地减少资本支出和设施面积。合约研发生产机构 (CDMO) 的强劲成长进一步推动了这一领域的扩张，这些机构越来越多地采用这些多功能係统来处理各种不同的产品线。正如 2024 年 CPHI 年度报告指出，49% 的受访製药企业高管对合约服务的未来成长持「非常乐观」的态度，这凸显了该行业对外部合作伙伴在推动高效工作流程方面的高度依赖。

儘管连续生物工艺具有诸多优势，但其广泛应用仍面临诸多挑战，主要与製程控制的复杂性和法规遵循有关。即时监测关键品质属性所需的高阶流程分析技术（PAT）构成了一项重要的技术门槛。此外，对连续自动化检验的需求，以及熟练掌握此类动态系统管理技能的人员短缺，都可能阻碍连续生物工艺的推广应用，尤其是在那些习惯于传统间歇式工艺的现有工厂中。

市场驱动因素

製程分析技术 (PAT) 和自动化技术的进步是全球连续生物製程市场的关键驱动力，它们能够实现即时品管并最大限度地减少人为错误。整合这些自动化系统使製造商能够持续监控关键程式参数，并在不停止生产的情况下即时修正偏差。虽然这种转型在技术上具有挑战性，但对于维持生物製药的严格监管标准至关重要，这促使製造商升级旧有系统。根据 CRB 于 2024 年 10 月发布的《展望：生命科学报告》，约 31% 的受访产业专业人士将数位化和自动化转型计划视为其下一个主要资本投资，这凸显了该产业对技术升级的重视。

向模组化和灵活化生产设施的转型将进一步推动市场成长，使企业能够快速回应不断变化的生产需求和多元化的产品平臺。与传统的固定式不銹钢设施相比，模组化单元可快速重新配置以适应不同的生产配置，从而显着降低多产品生产的进入门槛并减少设施占地面积。大型製药企业为提升生产敏捷性而进行的投资正是这一趋势的例证。根据《贝克尔医院评论》2024年11月一篇关于赛诺菲新工厂的报导，该公司正在新加坡建造一座价值6亿美元的工厂，旨在同时生产多达四种生物製剂。这项措施与整个产业的趋势相符：2024年CRB数据显示，四分之三的受访者目前已安装连续生产技术或计画在未来五年内安装。

市场挑战

连续生物製程的广泛应用主要受到严格的製程管制要求和相关监管不确定性的限制。与传统的间歇式製程不同，连续式工作流程需要即时监控和自动化回馈迴路来维持产品质量，这就需要先进的製程分析技术（PAT）。这种技术复杂性导致了陡峭的操作学习曲线，因为製造商必须确保动态控制系统持续稳定运作并检验。因此，许多公司对从成熟的间歇式製程转型持谨慎态度，担心无法向监管机构证明其控制的稳定性，可能导致违规和生产延误。

近期行业数据也印证了这种合规性方面的担忧：根据国际製药工程协会 (ISPE) 2024 年的一项调查，近 50% 的受访行业专业人士认为监管挑战是采用创新製造技术的最大障碍。这种不确定性直接限制了市场成长，製药开发商推迟了对连续生产线的资本投资，直到针对这些自动化系统的清晰、统一的法规结构完全建立并被其品管团队充分理解。

市场趋势

一次性技术与连续工作流程的融合，将一次性组件的柔软性与增强型灌注製程的高生产率相结合，正在革新全球连续生物製程市场。这种协同效应使製造商能够快速扩大生产规模，并显着降低资本支出，与传统的不銹钢设备相比，这对于在小规模的面积内生产多种生物製药产品至关重要。药明生物近期成功部署了超高生产率的连续生产平台，证明了这种混合方法的商业性可行性。根据该公司于2025年3月发布的2024财年财务报告，药明生物运作三个5000公升的一次性生物反应器用于商业化生产，使每克蛋白质的生产成本降低了约70%。这表明，为了保持成本竞争力，整个产业正在果断地转向整合式一次性连续生产系统。

同时，随着细胞和基因治疗领域从临床研究走向商业化生产，连续培养方法在该领域的应用也正在加速发展。为了因应这些复杂治疗方法所面临的规模化挑战和高昂的生产成本，研发人员正在加速从人工批次处理过程向自动化、封闭式连续工作流程的转型。这一趋势的驱动力是大量资金涌入，用于推动先进治疗方法生产流程的产业化。根据再生医学联盟于2025年1月发布的《产业趋势简报》，2024年全球对细胞和基因治疗领域的投资将年增30%，显示市场有强烈的意愿克服生产瓶颈。资金的激增正在推动连续技术的应用，而这些技术对于满足患者对救命治疗方法日益增长的需求至关重要。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章：全球连续生物製程市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 副产品（层析法系统及耗材、生物反应器、过滤系统及设备、其他）
  • 按流程（下游流程、上游工程）
  • 按应用领域（单株抗体、疫苗、细胞/基因疗法等）
  • 依最终用户（製药/生物製药公司、合约研究组织、学术研究机构、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美连续生物製程市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲连续生物製程市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区连续生物製程市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲连续生物製程市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲连续生物製程市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球连续生物製程市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific Inc.
• 3M Company
• Merck KgaA
• Sartorius AG
• Eppendorf SE
• Corning Incorporated
• Meissner AG
• OmniBRx Biotechnologies Private Limited
• Bio-Rad Laboratories, Inc.
• Fujifilm Holdings Corporation

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Continuous Bioprocessing Market is projected to expand from USD 264.87 Million in 2025 to USD 464.39 Million by 2031, registering a CAGR of 9.81%. This sector revolves around a manufacturing method where biological materials flow continuously through processing units, allowing for the simultaneous addition of raw media and the harvesting of the final product. The primary motivation behind this approach is the need to minimize capital expenditures and facility footprints while simultaneously boosting productivity and flexibility for multi-product manufacturing. This expansion is further bolstered by the strong growth of contract development and manufacturing organizations (CDMOs), which are increasingly adopting these versatile systems to handle diverse pipelines. As noted in the CPHI Annual Report for 2024, 49% of pharmaceutical executives surveyed expressed a 'very positive' outlook on the future growth of contract services, underscoring the industry's dependence on external partners who advocate for these efficient workflows.

Despite these benefits, the widespread adoption of continuous bioprocessing encounters significant hurdles related to the complexity of process control and regulatory alignment. The necessity for advanced Process Analytical Technology (PAT) to monitor critical quality attributes in real-time establishes a substantial technical barrier to entry. This requirement for continuous, automated validation, combined with a shortage of personnel skilled in managing such dynamic systems, can impede implementation efforts, particularly for legacy facilities that are accustomed to traditional batch processing.

Market Driver

Advancements in Process Analytical Technology and Automation serve as a primary catalyst for the Global Continuous Bioprocessing Market by facilitating real-time quality control and minimizing human error. Integrating these automated systems enables manufacturers to monitor critical process parameters continuously, ensuring that deviations can be corrected immediately without halting production. Although this shift is technically demanding, it is essential for upholding the rigorous standards mandated by regulatory bodies for biological products, thereby prompting manufacturers to upgrade legacy systems. According to the 'Horizons: Life Sciences Report' published by CRB in October 2024, approximately 31% of industry professionals surveyed identified digitalization and automation conversion projects as their next primary capital focus, highlighting the sector's dedication to technological upgrades.

The move toward modular and flexible manufacturing facilities further drives market growth by enabling companies to adapt rapidly to changing production requirements and diverse product pipelines. In contrast to traditional fixed stainless-steel facilities, modular units allow for quick reconfiguration to accommodate different modalities, which significantly lowers the barrier to entry for multi-product manufacturing and reduces facility footprints. This trend is illustrated by major pharmaceutical investments aimed at agility; as reported by Becker's Hospital Review in November 2024 regarding Sanofi's new manufacturing plant, the company is establishing a $600 million facility in Singapore designed to produce up to four biopharmaceuticals simultaneously. This initiative aligns with broader industry trends, as CRB data from 2024 indicates that three-quarters of respondents are currently using or planning to implement continuous technologies within the next five years.

Market Challenge

The widespread adoption of continuous bioprocessing is significantly hindered by the rigorous demands of process control and associated regulatory uncertainties. Unlike traditional batch methods, continuous workflows necessitate real-time monitoring and automated feedback loops to preserve product quality, requiring advanced Process Analytical Technology (PAT). This technical complexity results in a steep operational learning curve, as manufacturers must ensure that dynamic control systems remain validated without interruption. Consequently, many companies are hesitant to transition from established batch processes, fearing that an inability to demonstrate consistent control to regulators could result in compliance failures and production delays.

This apprehension regarding compliance is supported by recent industry data. According to the International Society for Pharmaceutical Engineering (ISPE) in 2024, nearly 50% of surveyed industry professionals cited regulatory challenges as the most significant barrier to adopting innovative manufacturing technologies. This prevailing uncertainty directly restricts market growth, as pharmaceutical developers delay capital investments in continuous lines until clear, harmonized regulatory frameworks for these automated systems are fully established and comprehended by their internal quality teams.

Market Trends

The integration of Single-Use Technologies into continuous workflows is revolutionizing the Global Continuous Bioprocessing Market by merging the flexibility of disposable components with the high volumetric productivity of intensified perfusion processes. This synergy permits manufacturers to scale operations rapidly and significantly lower capital expenditures compared to traditional stainless-steel setups, which is a critical advantage for producing diverse biologics within smaller facility footprints. The commercial viability of this hybrid approach was recently validated by WuXi Biologics, which successfully deployed its ultra-high productivity continuous platform at a commercial scale. According to the company's '2024 Annual Results' released in March 2025, WuXi Biologics commissioned three 5,000-liter single-use bioreactors for commercial production, contributing to a cost reduction in protein production per gram of nearly 70%, highlighting the sector's decisive shift toward integrated single-use continuous systems to maintain cost-competitiveness.

Simultaneously, the application of continuous methods to Cell and Gene Therapies is gaining momentum as the sector matures from clinical research to commercial-scale manufacturing. Developers are increasingly transitioning from manual, labor-intensive batch processes to automated, closed continuous workflows to tackle the urgent challenges of scalability and the exorbitant production costs associated with these complex modalities. This trend is driven by a robust influx of capital aimed at industrializing advanced therapy manufacturing. According to the Alliance for Regenerative Medicine's 'State of the Industry Briefing' in January 2025, global investment in the cell and gene therapy sector rose by 30% in 2024, signaling a strong market commitment to overcoming manufacturing bottlenecks. This surge in funding fosters the adoption of continuous technologies that are essential for meeting the growing patient demand for these life-saving therapies.

Key Market Players

• Thermo Fisher Scientific Inc.
• 3M Company
• Merck KgaA
• Sartorius AG
• Eppendorf SE
• Corning Incorporated
• Meissner AG
• OmniBRx Biotechnologies Private Limited
• Bio-Rad Laboratories, Inc.
• Fujifilm Holdings Corporation

Report Scope

In this report, the Global Continuous Bioprocessing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Continuous Bioprocessing Market, By Product

• Chromatography Systems and Consumables
• Bioreactors
• Filtration Systems and Devices
• Others

Continuous Bioprocessing Market, By Process

• Downstream
• Upstream

Continuous Bioprocessing Market, By Application

• Monoclonal Antibodies
• Vaccines
• Cell and Gene Therapy
• Other

Continuous Bioprocessing Market, By End-User

• Pharmaceutical and Biopharmaceutical Companies
• Contract Research Organizations
• Academic and Research Institutes
• Others

Continuous Bioprocessing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Continuous Bioprocessing Market.

Available Customizations:

Global Continuous Bioprocessing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Continuous Bioprocessing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Chromatography Systems and Consumables, Bioreactors, Filtration Systems and Devices, Others)
  • 5.2.2. By Process (Downstream, Upstream)
  • 5.2.3. By Application (Monoclonal Antibodies, Vaccines, Cell and Gene Therapy, Other)
  • 5.2.4. By End-User (Pharmaceutical and Biopharmaceutical Companies, Contract Research Organizations, Academic and Research Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Continuous Bioprocessing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Process
  • 6.2.3. By Application
  • 6.2.4. By End-User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Continuous Bioprocessing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Process
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End-User
  • 6.3.2. Canada Continuous Bioprocessing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Process
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End-User
  • 6.3.3. Mexico Continuous Bioprocessing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Process
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End-User

7. Europe Continuous Bioprocessing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Process
  • 7.2.3. By Application
  • 7.2.4. By End-User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Continuous Bioprocessing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Process
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End-User
  • 7.3.2. France Continuous Bioprocessing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Process
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End-User
  • 7.3.3. United Kingdom Continuous Bioprocessing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Process
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End-User
  • 7.3.4. Italy Continuous Bioprocessing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Process
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End-User
  • 7.3.5. Spain Continuous Bioprocessing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Process
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End-User

8. Asia Pacific Continuous Bioprocessing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Process
  • 8.2.3. By Application
  • 8.2.4. By End-User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Continuous Bioprocessing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Process
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End-User
  • 8.3.2. India Continuous Bioprocessing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Process
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End-User
  • 8.3.3. Japan Continuous Bioprocessing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Process
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End-User
  • 8.3.4. South Korea Continuous Bioprocessing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Process
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End-User
  • 8.3.5. Australia Continuous Bioprocessing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Process
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End-User

9. Middle East & Africa Continuous Bioprocessing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Process
  • 9.2.3. By Application
  • 9.2.4. By End-User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Continuous Bioprocessing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Process
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End-User
  • 9.3.2. UAE Continuous Bioprocessing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Process
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End-User
  • 9.3.3. South Africa Continuous Bioprocessing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Process
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End-User

10. South America Continuous Bioprocessing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Process
  • 10.2.3. By Application
  • 10.2.4. By End-User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Continuous Bioprocessing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Process
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End-User
  • 10.3.2. Colombia Continuous Bioprocessing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Process
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End-User
  • 10.3.3. Argentina Continuous Bioprocessing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Process
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Continuous Bioprocessing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. 3M Company
• 15.3. Merck KgaA
• 15.4. Sartorius AG
• 15.5. Eppendorf SE
• 15.6. Corning Incorporated
• 15.7. Meissner AG
• 15.8. OmniBRx Biotechnologies Private Limited
• 15.9. Bio-Rad Laboratories, Inc.
• 15.10. Fujifilm Holdings Corporation

16. Strategic Recommendations

17. About Us & Disclaimer